Korean Circ J.  2023 Oct;53(10):720-721. 10.4070/kcj.2023.0208.

Is High Plasma Homocysteine a Direct Cause of Cardiovascular Disease and Mortality?

• Hwang KK

• KMID: 2546996
• DOI: http://doi.org/10.4070/kcj.2023.0208

Reference

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56:111–128. PMID: 5792556.

2. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995; 332:328–329. PMID: 7654269.

3. Arafa A, Lee HH, Eshak ES, et al. Modifiable risk factors for cardiovascular disease in Korea and Japan. Korean Circ J. 2021; 51:643–655. PMID: 34227266.

4. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338:1042–1050. PMID: 9535670.

5. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019; 10:486–496. PMID: 30861319.

6. Choi CK, Kweon SS, Lee YH, et al. Association between plasma homocysteine level and mortality: a Mendelian randomization study. Korean Circ J. 2023; 53:710–719. PMID: 37559417.

7. Fan R, Zhang A, Zhong F. Association between homocysteine levels and all-cause mortality: a dose-response meta-analysis of prospective Studies. Sci Rep. 2017; 7:4769. PMID: 28684797.

8. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170:1622–1631. PMID: 20937919.

9. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017; 8:CD006612. PMID: 28816346.

10. Wang X, Chen Z, Tian W, et al. Plasma homocysteine levels and risk of congestive heart failure or cardiomyopathy: a Mendelian randomization study. Front Cardiovasc Med. 2023; 10:1030257. PMID: 36776266.